Registered title, quoted from ClinicalTrials.gov
Effect and Safety of Huaier Granule Versus SOX Regimen in Gastric Cancer Patients
An open trial on stomach cancer, registered on ClinicalTrials.gov. Led by Union Hospital; 1 other hospital on this site is listed as study site.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 2
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
- Lead sponsorUnion Hospital华中科技大学同济医学院附属协和医院WuhanHospital page
- Study siteAffiliated Hospital of Qingdao University青岛大学附属医院QingdaoHospital page
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT05498766, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 5
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (5 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
Pathologically diagnosed as stage II or III gastric adenocarcinoma (including gastroesophageal junction).
Inclusion criterion 2
Receiving radical surgery (R0, D2 resection, more than 16 lymph nodes should be detected) for gastric adenocarcinoma within 2 months prior to enrollment, and not receiving adjuvant treatment.
Inclusion criterion 3
Eastern Cooperative Oncology Group (ECOG) performance status from 0 to 2.
Inclusion criterion 4
Pregnant or lactating women or women prepare for pregnancy.
Exclusion criterion 8
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT05498766, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- 18-75 years
- Pathologically diagnosed as stage II or III gastric adenocarcinoma (including gastroesophageal junction).
- Receiving radical surgery (R0, D2 resection, more than 16 lymph nodes should be detected) for gastric adenocarcinoma within 2 months prior to enrollment, and not receiving adjuvant treatment.
- Eastern Cooperative Oncology Group (ECOG) performance status from 0 to 2.
- Patients are volunteers, have signed informed consent, and agree to cooperate with investigators in data collection.
Exclusion Criteria:
- Patients had received neoadjuvant therapy.
- Patients who have received or plan to receive targeted therapy and/or immunotherapy。
- Patients allergic to the components of Huaier granules, or avoid to use Huaier granules or use with caution.
- More than two active primary tumors at the same time.
- Patients have not recovered from surgical complications after radical surgery.
- Patients received other Chinese patent medicine with anti-tumor effects.(including but not limited to Huaier Granule, Fufangbanmao Capsule, Huachansu Capsule, Kangai Injection, Pingxiao Table) in the past 1 month.
- Not able to take medication orally cause by difficulty in swallowing, complete or incomplete gastrointestinal obstruction, active bleeding from the gastrointestinal tract, perforation, etc.
- Pregnant or lactating women or women prepare for pregnancy.
- Serious concomitant infection disease.
- Patients with severe psychiatric illness or otherwise diseases are unsuitable for this study according to the judgment by investigators.
- Patients with combined immune disease and receiving immunosuppressive therapy.
Quoted from ClinicalTrials.gov, NCT05498766, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT05498766, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.